Prionics AG | Date: 2017-03-29
The present disclosure, according to one embodiment, describes a laboratory vessel for storing and treating a tissue sample comprises a closable opening, and additionally comprises a pipe part which is insertable in the opening of the laboratory vessel, wherein in inserted position, the pipe part seals against the laboratory vessel with its outer circumference and is clampingly displaceable with respect to said laboratory vessel, wherein a pestle is mounted in the laboratory vessel, over which the pipe part can be placed sealingly with its inner circumference. The laboratory vessel also comprises one or more tissue sample treatment agents. The tissue sample and the treatment agents are separated by placing the pipe part over the pestle, which separates a treatment agent region from a sample region.
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2013-1 | Award Amount: 1.56M | Year: 2013
DeTECH21 will provide through SME led and directed research new forensic testing services based on metabolomic profiling which will identify the misuse of prohibited and licensed chemicals in bovine and equine animals. The new services which the SME partners will obtain from the project will offer an innovative approach to drug analysis based on the monitoring of biological responses to drug use in animals rather than on the direct detection of compounds which forms the basis of current testing. The administration of both legal and illegal drugs to animals destined for food production and performance sport competition continues to be an enormous challenge. Current testing typically analyses individual samples for a single specific drug and thus is inefficient and costly. These limitations have become evident through sport anti-doping enforcement where similar testing has proved ineffectual with individuals proven to have continually evaded detection despite sustained testing. These challenges have been identified by SME partners as challenges to their long-term business sustainability. DeTECH21 aims to deliver new services to increase SME competiveness, service cost-effectiveness and market reach. This will be achieved through the use of the skills of RTD partners in innovative sample profiling techniques and the skills of SME partners in the commercial provision of analytical services. The uniqueness and innovation of the DeTECH21 project will lie in the construction of metabolomic databases which can be used to identify animals which have been exposed to exogenous substances and assist in the identification of administered compounds. This 2 year project brings into collaboration key partners from across Europe who have come together with the joint objective of delivering what will be the first commercially available forensic test service based on metabolomic analysis applicable to food safety and performance animal applications.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2011.1.3-02 | Award Amount: 4.33M | Year: 2012
This proposal addresses the call under KBBE.2011.1.3-02: Development of field test for rapid screening of pathologies as well as simple laboratory test in animals. Sustainable food production capable of feeding a growing global population is a significant challenge that is faced by agricultural industries throughout the world. The demand for safe, efficient and high quality animal protein will rise significantly over the next decade with a concomitant increase in the world population of domesticated livestock. Infectious diseases continue to impact upon the productivity of farm animals and threats of disease incursions are further increased by the globalised trade of animals and animal products. Rapid and reliable diagnostic systems can play an integral role in the detection, monitoring, control and subsequent eradication of animal diseases and pathologies. This proposal will develop and bring to market new tools to achieve effective diagnosis of livestock, companion animal and wildlife diseases. The project RAPIDIA-FIELD will develop multiplex pen-side tests that can be used to support local decision-making by animal health practitioners. These tests will be simple to perform, robust, inexpensive and also provide unambiguous results for easy reporting. This concept also includes work to develop test formats for use in non-specialised front-line laboratories. In addition to the development of the specific tests and assay platforms, the project will also consider how these tests will be used in the field or in local laboratories, and how data generated by the assays will integrate with other new (and existing) systems that contribute to the diagnosis, monitoring, control and subsequent eradication of animal diseases. Aspects of this work will include real-time monitoring on line of animal health on farms to collect parameters such as feed consumption and water intake as well as using thermography or thermal chip to look for early signs of clinical disease. Together with the data generated by the assays, reporting protocols will also be established to ensure that the critical information collected is correctly archived and is traceable to international quality standards. The project will also pay some attention to new technologies and protocols only carried out in sophisticated laboratories. The idea of this work is to position animal health in a new frontier of science that will maximise our chance to identify new diseases and problems before they become overt health threats. Concluding, the proposed strategy is devoted to define, develop and bring to the society products and services that contribute to Animal Health control at field level.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.1.4-07 | Award Amount: 1.56M | Year: 2013
Recent studies have showed estimations of worldwide 50 million cattle infections with M. bovis, at a cost to the agricultural community of 2-3 billion per year. In developing countries, M. bovis infection is still widespread, in both cattle and humans. Even in developed countries, successful eradication of disease from livestock is hampered by the presence of wildlife reservoirs of M. bovis. Under these circumstances, a single case of a reportable disease in livestock can result in serious economic consequences for the producer, public, and governments. Within this scenario, theres room and clear business opportunities for integrated control products or solutions that aim at addressing what is considered a global problem, animal tuberculosis. Our overall objective is therefore to take the results of the TB-STEP project - Strategies for the eradication of bovine tuberculosis, funded under FP7-KBBE-2007 with project number 212414, where most of the WildTBVac partners were involved, and build a pre-commercial set of TB control solutions by means of testing the technical and economical viability of the aforementioned integrated approach. WildTBVac specific objectives are the following: To standardize and optimize the production of a TB Vaccine (prototype resulting of the TB-STEP project) To evaluate several vaccine-compatible diagnostic strategies (also resulting from the TB-STEP project) that will include multi-species DIVA tests (wild boar, domestic pigs, cattle) To assess the field efficacy of integrated TB control strategies including oral vaccination for TB control in wild boar To evaluate the field efficacy of integrated TB control strategies including oral vaccination for TB control in domestic and feral pigs To define the exploitation and commercialization strategy including clear technology transfer approaches and development of a market oriented business.
Prionics AG | Date: 2013-06-10
Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: SME-2013-3 | Award Amount: 691.20K | Year: 2013
Tuberculosis (TB) in humans and bovine TB in farm animals are global health problems of immense social and economic importance. Human TB: Mycobacterium tuberculosis (M.tb) is a slowly replicating bacillus that resides intracellularly within phagosomes of macrophages and commonly causes latent infections of the lung and in about 5% of the infected individuals it leads to active disease. Co-infection with M. tuberculosis is estimated in about one-third of HIV-1 infected subjects. Indeed, the risk of developing M. tuberculosis as an opportunistic infection is increased up to 200-fold in HIV-1\ subjects. Drug resistance to HIV-treatment and appearance of multiple-drug resistance (MDR) and off late of Extra-Drug Resistance (XDR) strains of M. tuberculosis, the causative agent of human TB is steadily leading to a hopeless situation as far as the therapy is concerned.Bovine TB: Bovine tuberculosis is caused by the bacterium Mycobacterium bovis, which is closely related to Mycobacterium tuberculosis, the cause of human tuberculosis. M. bovis can be transmitted to humans through the ingestion of unpasteurised milk and milk products as well as aerosols, from infected cows. The introduction of pasteurisation eliminated transmission through contaminated milk and greatly reduced the human health problem1. The principal hosts for bovine tuberculosis are cattle and buffalo, however many other domestic and wild animals can become infected e.g. goats, cervids, pigs, wild boars, dogs, cats, camels, badgers, primates, hares, amongst others. Bovine tuberculosis is found worldwide. All developed countries currently have a TB eradication program in place for many years. These programs have been largely successful; however, incidences are increasing in many countries (e.g. UK, Ireland, France, Austria, Germany). The specific objectives achievable within DEMO-NOPERSIST project are 1. Development and evaluation of prototype test kits for active human TB (LIONEX, SME). This test shall be the Worlds first blood test for discriminating latent from active TB in humans. 2. Development and evaluation of prototype test kits for active Bovine TB (PRIONICS, SME) 3. To develop marketable, improved diagnostic products for human and bovine TB within a period of 2-3 years . Thus, both human and bovine active TB tests are directly linked to the NOPERSIST project and shall be an excellent demonstration of a Res4SME project NOPERSIST.
Prionics Ag | Date: 2014-05-14
Method for the detection and classification of PRRSV-infections in swine herds, comprising a) the incubation of tissue samples taken from the animals with at least one antigen capable to bind a neutralizing antibody against the Type I-virus possibly present in the animal and with at least one antigen capable to bind a neutralizing antibody against the Type II-virus possibly present in the animal, b) testing whether a binding of antibodies against the Type I-virus and/or the Type II-virus has taken place and c) determining from the presence of possible epitope-antibody complexes whether an infection of the PRRSV I-Type and/or PRRSV II-Type is present in the herd and diagnostic compositions for such a method.
Prionics Ag | Date: 2015-12-28
The present specification relates to apparatus, methods and kits for applying an identification tag to an animal and removing a tissue sample from the animal. Apparatus of the disclosure cannot be manipulated to transfer an identification tag from one animal to another. An apparatus can comprise a sample container, a flap, a downholder clip and a cutting element that can be placed on a male part of an ear-tag and at least one element/feature that supports movement of the sample container out of the movement path of the male tag toward the female part of the ear-tag.
Prionics AG | Date: 2014-11-19
Method for the detection and classification of PRRSV-infections in swine herds, comprising a) the incubation of tissue samples taken from the animals with at least one antigen capable to bind a neutralizing antibody against the Type I-virus possibly present in the animal and with at least one antigen capable to bind a neutralizing antibody against the Type II-virus possibly present in the animal. b) testing whether a binding of antibodies against the Type I-virus and/or the Type II-virus has taken place and c) determining from the presence of possible epitope-antibody complexes whether an infection of the PRRSV I-Type and/or PRRSV II-Type is present in the herd and diagnostic compositions for such a method..
Prionics Ag | Date: 2014-07-24
To attach an ear tag (6, 10) to an ear (16) and to remove a sample (22) containing tissue of the ear therefrom, a mandrel (8), which is fastened to a mandrel region (6) of the ear tag, is brought by means of pliers (1) on a first movement path through the ear (16) into a hole (12) formed in a hole part (10) of the ear tag and anchored there, while the sample (22) is taken with the aid of a removal head (17) and is brought out of engagement with the hole (12) by interaction with the mandrel (8) with a movement component oriented transversely to the first movement path, before the mandrel (8) is anchored in said hole.